Andere Sprachen Agenus Inc.

Aktien

A403RK

US00847G8042

AGEN

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:18:54 20.06.2024			% 5 Tage	% 1. Jan.
13,14 ^USD	+1,12 %		-18,19 %	-20,94 %

17.06.	Agenus ernennt Jennifer Buell zum Mitglied des Vorstands	CI
12.06.	Transcript : Agenus Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors	17.06.
Agenus Appoints Jennifer Buell to Its Board of Directors	17.06.
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50	13.06.
US FDA approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk \| GSK	10.06.
Agenus Announces Virtual Annual Shareholders Meeting	04.06.
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	24.05.
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting	23.05.
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference	23.05.
Botensilimab (BOT) plus balstilimab (BAL) in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites	20.05.
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	16.05.
Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	16.05.
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	07.05.
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07.05.
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M	07.05.
Agenus: Q1 Earnings Snapshot	07.05.
Agenus Reports First Quarter 2024 Results	07.05.
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program	07.05.
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement	01.05.
Agenus Inc. - Botensilimab, Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting	25.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Agenus Inc.

Aktien

A403RK

US00847G8042

AGEN

Andere Sprachen

Filter